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progression of knee pain. The KOACAD system will be useful for objective
evaluation of the disease severity in daily clinical practice, just as bone
mineral density is in osteoporosis.
467 NEUROPATHIC PAIN SYMPTOM MEASURES STRIKE A
NERVE IN OSTEOARTHRITIS
J. Hochman1, D. Sutton1, M. French1, L. Gagliese2, A. Davis3,
G. Hawker1. 1Women’s College Hospital, Toronto, ON, CANADA,
2University Health Network, Toronto, ON, CANADA, 3Toronto Western
Hospital Research Institute, Toronto, ON, CANADA
Purpose: Pain is the most common, disabling symptom for people
with Osteoarthritis (OA). Cumulative data suggests dysfunctional pain
processing by the central nervous system, called central sensitization
(CS), contributes to pain in OA. CS can be associated with the neuro-
pathic pain (NP) symptom proﬁle including burning, electric-shock like
sensations, and sensitivity to light touch. Improved understanding of pain
mechanisms in OA, including development of “clinically feasible” tools to
identify individuals likely to have CS would facilitate development of novel
mechanism-based pain therapies. This ongoing study is assessing (1) NP
symptoms in subjects with symptomatic knee OA, using a NP question-
naire modiﬁed for use in OA, the modiﬁed painDETECT (mPD-Q), and the
Self-completed Leeds Assessment of Neuropathic Symptoms and Signs
pain scale (S-LANSS), which has been validated in other chronic pain
populations; (2) pain intensity, using the Von Korff Chronic Pain Grade
Scale (CPG) and, (3) co-morbid chronic pain and neurological conditions.
Methods: Eligible study subjects are members of an existing population-
based OA cohort with chronic symptomatic knee OA deﬁned by pain,
discomfort and/or stiffness in the knee(s) on most days for  3 months.
A standardized questionnaire was mailed to 268 cohort members to date,
to assess (1) pain quality for each knee using the mPD-Q, scored -1 to
38; and the S-LANSS, scored 0−24; (2) pain intensity, using the CPG,
scored 0–100; and (3) co-morbid conditions. Mean, median, and standard
deviation (SD) were evaluated for questionnaire scores. The proportion of
knee OA cohort participants with mPD-Q and S-LANSS scores in the ‘NP
range’ (mPD-Q score 19, S-LANSS score 12) was calculated using a
95% conﬁdence interval. Pearson correlations between mPD-Q and other
questionnaire scores (SLANSS and CPG) were examined.
Results: To date, 129 (48%) questionnaires have been returned. Thirty-
two (29%) responders reported no chronic knee pain. Among 92 (71%)
responders with chronic knee pain, 73 had chronic right and 63 had
chronic left knee pain. Mean (SD) mPD-Q scores were the same, 12 (7),
for right and left knees. Mean (SD) S-LANSS scores were 8 (8) for right
knees and 7 (7) for left knees. According to cut-points identiﬁed in other
pain populations, the proportion (95%CI) of study subjects with scores in
the ‘NP range’ on the mPD-Q was 0.21 (0.12−0.32) for right knees and
0.17 (0.08−0.28) for left knees; on the S-LANSS was 0.31 (0.20−0.42) for
the right knees and 0.25 (0.14−0.36) for left knees. The mPD-Q scores
had a moderate to high correlation with the S-LANSS scores for right
(r = 0.68) and left knees (r = 0.73). The mPD-Q scores had a moderate
correlation with CPG pain intensity scores for right (r = 0.61) and left
(r = 0.65) knees. The following factors did not explain the variability seen
in mPD-Q scores: presence of diabetes, another chronic pain condition,
a co-morbid neurological condition.
Conclusions: In a population-based cohort with chronic knee OA, almost
a quarter of subjects with painful knee OA scored in the ‘NP range’ on
both of the measures assessed. This subgroup of patients may beneﬁt
from further evaluation for NP likely due to CS and consideration of NP
medications. Further validation work on the mPD-Q is ongoing.
468 FURTHER VALIDATION OF OARSI-OMERACT INTERMITTENT
AND CONSTANT OSTEOARTHRITIS PAIN (ICOAP) MEASURE
G.A. Hawker1, M.R. French1, A.M. Davis2, P. Dieppe3. 1Women’s
College Hospital, Toronto, ON, CANADA, 2Toronto Western Research
Institute, Toronto, ON, CANADA, 3University of Oxford, Oxford, UNITED
KINGDOM
Purpose: To further assess the construct validity of ICOAP, a new
osteoarthritis (OA) pain measure.
Methods: The new measure, ICOAP, is comprised of 5 items assessing
‘constant’ hip or knee pain and 6 items assessing ‘intermittent’ hip or
knee pain; item response options are on a 4-point scale from ‘not at all’
to ‘extremely’. Subscale and total scores are standardized to 0 to 100,
where higher scores indicate worse pain. The ICOAP was administered
by phone to an established community cohort aged 55+ years with
moderate to severe hip and/or knee OA. All subjects completed both
the hip and knee versions of the ICOAP, regardless of which joints were
painful at the time. Participants also completed other measures of arthritis
pain and disability (WOMAC pain, function and stiffness subscales;
McGill pain intensity scale, and the limitation dimension of the Late
Life Function and Disability Instrument), the Proﬁle of Mood States-Brief
(POMS) fatigue/inertia scale, the SF-36 general health perception scale,
the CES-D scale for depressed mood, the Lubben Social Network Scale,
and the Pain Catastrophizing Scale. Summary descriptive statistics were
calculated for all scale scores. Spearman’s rho correlation coefﬁcients
were calculated to assess the relationship between ICOAP Hip and Knee
subscale and total scores with each of the other measures. T-tests were
used to compare means ICOAP scores for men versus women.
Results: The mean age of the 659 participants was 77.6 years (58.7 to
97.9), 77.4% were female and 23.7% had < high school education; 631
had complete data for ICOAP Hip and 608 for ICOAP Knee. Mean score
(SD) for the hip was 26.8 (SD 25.0) and 18.0 (SD 26.8) for intermittent and
constant pain, respectively. For the knee, mean intermittent and constant
pain scores were 30.9 (SD 23.3) and 16.0 (SD 26.5), respectively. Women
had higher intermittent and total ICOAP pain scores than men (hip and
knee results similar, p< 0.05 for all). Within individuals, intermittent and
constant pain scores were only modestly correlated (r = 0.29 for the knee;
r = 0.46 for the hip, p< 0.0001 for both) and their strength of association
with other measures differed (e.g. correlation with pain catastrophizing
score: intermittent pain r = 0.27 versus constant pain r = 0.39). For the
hip, measures of coping, fatigue, mood and physical functioning were
more strongly related to constant than to intermittent pain. For the
knee, the reverse was generally true, with stronger correlations being
associated with intermittent knee pain scores. ICOAP score correlations
with WOMAC pain scores ranged from 0.39 (hips; ICOAP intermittent
pain) to 0.65 (knees; ICOAP total pain). Higher scores for both intermittent
and constant pain were associated with lower general health status,
higher scores on other pain and disability measures, higher scores for
depression, fatigue and pain catastrophizing, and lower scores for social
support.
Conclusions: Our results provide further evidence of the ICOAP as a
valid tool for evaluation of pain in hip and knee OA and supports use of
the two subscale scores for intermittent and constant pain independently
as distinct and important domains of OA pain.
469 C-REACTIVE PROTEIN LEVELS ARE ASSOCIATED WITH
OA-RELATED KNEE PAIN IN WOMEN
H.J. Kerkhof, M. Sharma, S. Bierma-Zeinstra, H.A. Pols,
A.G. Uitterlinden, J.B. van Meurs. Erasmus Medical Center, Rotterdam,
NETHERLANDS
Purpose: Four previous studies (n = 1675) have shown that C-Reactive
Protein (CRP) levels are associated with (progression of) knee os-
teoarthritis (KOA). At this moment, there are only three studies (n = 968)
published, examining the relationship between CRP levels and joint
complaints or disability. In this population-based study, we analyzed the
association between CRP levels and KOA-related knee pain and the
relationship between CRP levels, body mass index (BMI) and KOA since
it is still not clear whether BMI plays a role as a confounder or as effect
mediator in this model.
Methods: In total, 1655 women from the Rotterdam Study had data
on radiographic knee OA, age, BMI and CRP levels. High-sensitivity
CRP measurements were performed using rate near-infrared particle
immunoassay. For all statistical analysis, log-transformed CRP values
were used. KOA was deﬁned as a Kellgren/Lawrence score 2 in one
or both knees. Knee pain was deﬁned as having pain in the right or left
knee during the last month or the past ﬁve years.
Results: Women with knee OA had 30% higher CRP levels compared
to women without KOA (p = 8×10−7), but after adjustment for age and
BMI this association disappeared (p = 0.3). We next stratiﬁed our data
according to BMI, to investigate the role of BMI as an effect modiﬁer. We
observed that women with a BMI< 27.0 kg/m2 and with KOA had 34%
higher levels of CRP compared to women without KOA (p = 0.004 after
adjustment for age and co-morbidity). Importantly, this association was
absent in women with a BMI> 27.0 kg/m2 (p = 0.63). CRP levels were
borderline signiﬁcant associated with an increased risk of knee pain in
our study (p = 0.053 after adjustment for age and BMI). This effect was
only visible in women with radiographic KOA (27% higher CRP levels,
p = 0.03 after adjustment for age and BMI) and not in women without
KOA (p = 0.43).
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Conclusions: We showed that CRP levels are associated with OA-
related knee pain in women. This might indicate that there is an in-
ﬂammatory component present in knee OA that contributes to knee pain
experienced in OA. In addition, we showed that BMI modiﬁes the effect
of CRP levels on KOA. This may indicate a difference in pathogenesis of
OA in overweight women compared to women with a healthy weight. For
example, mechanical load is a major contributor in overweight women,
whilst in women with a healthy weight systemic inﬂammation might play
a more prominent role.
Another explanation could be that we do not see the effect in overweight
women because of confounding by co-morbidity such as cardiovascular
disease or diabetes, although we tried to adjust for this in our analysis.
470 COMPARING PLACEBO RESPONSE IN NORTH AMERICAN
AND EUROPEAN PATIENTS WITH KNEE OA
S.J. Bartlett, C.O. Bingham III. Johns Hopkins, Baltimore, MD, USA
Purpose: In OA trials, rates of placebo response are often 50%+. Despite
this, little is known about sociodemographic or clinical predictors. We
hypothesized that rates of response and predictors would be similar
between patients in North America (NA) vs. Europe (EUR).
Methods: Data were drawn from 622 males and females randomized
to the placebo arm of a large multinational clinical trial designed to
evaluate the clinical effects of a bisphosphonate on knee OA. Patients
were 40−80 years of age who reported knee pain due to OA on most
days during 1 of the prior 3 months, morning stiffness lasting <30min or
knee crepitus according to the ACR criteria for knee OA. No minimum
level of pain was required. Patients also had 1+ osteophytes, joint space
width (JSW) of 2−4mm in the medial tibiofemoral compartment, and a
medial compartment < lateral. WOMAC pain and function scales were
administered at baseline and 6 months. OARSI 2004 Responder Criteria
were used to classify participants at 6 months.
Results: 552 (83%) patients completed the 6 month evaluations. Overall,
patients were mostly female (63%) and white (79.2%) with a mean (±SD)
age of 62.0±8.8 years, BMI of 29.8±4.6, and JSW of 3.0±0.6mm. EUR
patients were signiﬁcantly (p< 0.01) older, more likely to be female, lighter
and use less analgesic medication. EUR patients also had signiﬁcantly
(p< 0.01) higher WOMAC pain, function and patient global assessment
scores at baseline.
More participants in the EUR as compared to the NA sites met the
criteria for treatment response (23.5% vs. 21.0%, respectively), although
the difference was not statistically signiﬁcant (p = 0.488). A breakdown of
patients meeting criteria for high response and improvement by cohort is
shown below.
At baseline, placebo responders had signiﬁcantly lower scores for
WOMAC pain (31.6±1.5 vs. 41.6±1.1; p< 0.001), function (37.8±1.7
vs. 44.9±1.2; p< 0.001) and patient global assessment (50.2±2.2 vs.
55.4±1.1; p = 0.032). No statistically signiﬁcant differences were found
between responders and non-responders for age, gender, body mass
index, baseline JSW, OARS grade, osteophytes or use of pain medica-
tion. In multivariate logistic regression models, even with adjustment for
baseline sociodemographic and OA-related characteristics, baseline pain
was the only consistent predictor of placebo response in both joint and
separate models.
Conclusions: Using OARSI Response Criteria, more than 1 in 5 partic-
ipants who were in the placebo arm met stringent criteria for treatment
response. Responders were more likely to report moderate levels of pain
and impairments in physical function than non-responders at baseline.
Overall, there do not appear to be sociodemographic or OA-related
characteristics reliably associated with placebo response.
Pain: Pathophysiology
471 QUANTITATIVE SENSORY TESTING IN OSTEOARTHRITIS OF
THE KNEE
P.A. Dieppe1, S. Ayis2, S. Clarke2, D. Simmons2, S. Williams2,
M. Fallon3, L. Colvin3. 1University of Oxford, Oxford, UNITED
KINGDOM, 2University of Bristol, Bristol, UNITED KINGDOM,
3University of Edinburgh, Edinburgh, UNITED KINGDOM
Purpose: To assess skin sensitisation over the medial aspect of the knee
in people with osteoarthritis (OA) of the knee, using quantitative sensory
testing (QST) and relate this to their pain experiences
Methods: 28 patients with established medial compartment tibiofemoral
joint OA were recruited to the study. They were interviewed about pain,
and they completed WOMAC, HADs and MGill pain questionnaires. QST
was then used to assess any area of altered sensation in the skin, test
for mechanical sensitivity and pain thresholds, and assess skin thermal
sensitivity.
Results: The group included 20 women and 8 men with a mean age of
62.8 years, knee pain of an averge of 5 years duration, and radiographic
evidence of medial compartment knee OA. Their mean WOMAC and
HADs scores were 47.8 (range 16−73) and 14.2 (6−31) respectively.
26/28 had an area of altered sensation over the medial aspect of the index
knee. Sensitivity to touch was lower in that knee, but pain threshold higher
than in the contralateral knee. 19/28 had thermal allodynia, severe in 4.
Those with cold allodynia had higher WOMAC and HADs scores than
the whole group, and were more likely to use McGill pain descriptors
suggesting of neuropathic pain.
Conclusions: Sensory processing is altered in most patients with knee
OA, and in some cases neuropathic pain may make an important contri-
bution to the pain experience. This has implications for therapy.
472 SYNOVITIS INCREASES THE RISK OF KNEE PAIN
IRRESPECTIVE OF STATUS OF X-RAY OA: THE MOST
STUDY
K. Baker1, A. Grainger2, J. Niu1, M. Clancy1, A. Guermazi1, M. Crema1,
L. Hughes3, J. Buckwalter4, M. Nevitt5, D. Felson1. 1BUMC, Boston,
MA, USA, 2U Leeds, Leeds, UNITED KINGDOM, 3UAB, Birmingham,
AL, USA, 4U Iowa, Iowa City, IA, USA, 5UCSF, San Francisco, CA, USA
Purpose: Pain from knee OA is a key symptom in the decision to seek
medical care and an important antecedent to disability. Synovitis has
been hypothesized as one pathological feature that causes pain. Synovial
thickening on contrast enhanced (CE) MRI has been shown to correlate
well with synovitis on histology. On non CE MRIs synovial thickening
cannot be assessed and on these images synovitis has been weakly
and inconsistently associated with pain. We used CE MRIs, to assess
synovial thickening in relation to knee pain severity among subjects in
the Multicenter Osteoarthritis Study (MOST).
Methods: MOST is a NIH-funded longitudinal observational study of risk
factors for knee structural changes and occurrence of pain in persons age
50−79 with or at high risk of knee OA. An unselected subset of partici-
pants who volunteered obtained 1.5 CE MRI of one knee at the 30 month
clinic visit. Synovitis was scored 0−3 in 4 compartments (suprapatellar
pouch, medial and lateral parapatellar recesses and infrapatellar fat
pad) and 0−1 in 2 compartments (medial and lateral posterior condylar)
(Rheumatol 44:1569 2005). We categorized synovitis in the whole knee
as severe (>1 compartment scored 3), moderate (>2 compartments
scored 2 but no 3s), mild (>4 compartments scored 1 or 1 scored 2),
normal/questionable (<4 compartments scored as 1). Inter-reader kappa
was 0.9 (p< 0.001). Subjects were asked about their knee pain severity
using WOMAC. Each of the 5 items in the WOMAC pain scale is scored
from 0 (no pain) to 4 (extreme pain). We used the maximum item score
to deﬁne the categories of knee pain severity: no-pain (all 5 items scored
0 prior to a clinic visit), mild-pain (maximum score of any item 3). We
examined the association between synovitis and pain severity using a
logistic regression model adjusting for age, sex, BMI, MRI bone marrow
edema, and effusions. We also examined if the effect of synovitis on pain
severity was modiﬁed by radiographic OA status.
Table 1
All subjects Synovitis
Worst pain on any WOMAC
pain question
Normal/
questionable
(n = 151)
Mild (n = 233) Moderate/severe
(n = 69)
None (n = 158) 69 (46%) 79 (34%) 10 (15%)
Mild (n = 149) 45 (29%) 79 (34%) 25 (36%)
Moderate/severe/extreme
(n = 146)
37 (25%) 75 (32%) 34 (49%)
Adj OR for mild pain vs no
pain (95%CI)*
1.0 1.4 (0.9, 2.4) 3.1 (1.2, 8.0) p for trend 0.02
Adj OR for moderate/
severe/extreme pain vs no
pain (95%CI)*
1.0 1.9 (1.0, 3.3) 4.8 (1.8, 12.3) p for trend 0.001
Subjects KL< 2, no PF OA n=132 n=149 n=16
None 62 (47%) 61 (41%) 5 (31%)
Mild/moderate/severe/extreme 70 (53%) 88 (59%) 11 (69%)
Adj OR for pain (95%CI)* 1.0 1.4 (0.8, 2.3) 2.2 (0.6, 8.1) p for trend 0.15
*Adjusted for age, sex, BMI and MRI bone marrow edema and effusions
